智飞生物(300122.SZ)：带状疱疹mRNA疫苗获得临床试验批准通知书

Core Viewpoint - Zhifei Biological (300122.SZ) has received approval from the National Medical Products Administration for clinical trials of its mRNA vaccine for shingles, developed by its wholly-owned subsidiary Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd [1] Group 1 - The mRNA vaccine is specifically aimed at preventing shingles [1] - The approval notification number for the clinical trial is 2026LP00326 [1]